Rhumbline Advisers Sells 1,620 Shares of Natera, Inc. (NASDAQ:NTRA)

Rhumbline Advisers cut its position in shares of Natera, Inc. (NASDAQ:NTRA) by 1.2% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 138,281 shares of the medical research company’s stock after selling 1,620 shares during the quarter. Rhumbline Advisers owned approximately 0.10% of Natera worth $21,890,000 as of its most recent SEC filing.

Several other institutional investors have also recently modified their holdings of the company. Creative Planning grew its position in Natera by 18.3% during the 3rd quarter. Creative Planning now owns 5,833 shares of the medical research company’s stock worth $740,000 after acquiring an additional 904 shares during the last quarter. Private Advisor Group LLC grew its position in Natera by 5.2% during the 3rd quarter. Private Advisor Group LLC now owns 2,721 shares of the medical research company’s stock worth $346,000 after acquiring an additional 135 shares during the last quarter. Lecap Asset Management Ltd. grew its position in Natera by 8.2% during the 3rd quarter. Lecap Asset Management Ltd. now owns 7,003 shares of the medical research company’s stock worth $889,000 after acquiring an additional 531 shares during the last quarter. International Assets Investment Management LLC grew its position in Natera by 9,755.3% during the 3rd quarter. International Assets Investment Management LLC now owns 14,980 shares of the medical research company’s stock worth $1,902,000 after acquiring an additional 14,828 shares during the last quarter. Finally, Zweig DiMenna Associates LLC grew its position in Natera by 213.0% during the 3rd quarter. Zweig DiMenna Associates LLC now owns 242,625 shares of the medical research company’s stock worth $30,801,000 after acquiring an additional 165,100 shares during the last quarter. 99.90% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Natera

In other Natera news, CEO Steven Leonard Chapman sold 78,553 shares of the business’s stock in a transaction on Wednesday, January 22nd. The stock was sold at an average price of $164.97, for a total value of $12,958,888.41. Following the sale, the chief executive officer now directly owns 267,629 shares of the company’s stock, valued at approximately $44,150,756.13. The trade was a 22.69 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider John Fesko sold 663 shares of the business’s stock in a transaction on Thursday, February 6th. The stock was sold at an average price of $177.77, for a total value of $117,861.51. Following the completion of the transaction, the insider now owns 156,044 shares of the company’s stock, valued at $27,739,941.88. This represents a 0.42 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 295,772 shares of company stock worth $49,741,699. 7.60% of the stock is owned by insiders.

Natera Trading Down 2.6 %

NTRA opened at $168.19 on Friday. The stock has a market cap of $22.20 billion, a PE ratio of -95.56 and a beta of 1.66. The company has a quick ratio of 4.23, a current ratio of 4.39 and a debt-to-equity ratio of 0.33. The business has a 50 day moving average of $168.06 and a 200-day moving average of $144.78. Natera, Inc. has a 52 week low of $69.14 and a 52 week high of $183.00.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on NTRA. Barclays began coverage on Natera in a research report on Thursday, January 23rd. They set an “overweight” rating and a $200.00 price target on the stock. Sanford C. Bernstein raised their price target on Natera from $160.00 to $200.00 and gave the stock an “outperform” rating in a research report on Friday, January 10th. JPMorgan Chase & Co. increased their price objective on Natera from $160.00 to $200.00 and gave the stock an “overweight” rating in a report on Friday, December 13th. Robert W. Baird increased their price objective on Natera from $120.00 to $160.00 and gave the stock an “outperform” rating in a report on Wednesday, November 13th. Finally, StockNews.com cut Natera from a “hold” rating to a “sell” rating in a report on Thursday, November 14th. One equities research analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Natera presently has an average rating of “Moderate Buy” and a consensus price target of $170.94.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.